Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 29% Improvement Relative Risk Ventilation 50% ICU admission 21% Combined NIV/ICU/vent.. 15% primary c19colchicine.com Cecconi et al. Colchicine for COVID-19 RCT LATE TREATMENT Favors colchicine Favors control
Cecconi, 240 patient colchicine late treatment RCT: 29% lower mortality [p=0.62], 50% lower ventilation [p=0.29], 21% lower ICU admission [p=0.67], and 15% improvement [p=0.62] https://c19p.org/cecconi
copied to clipboard
Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial
Cecconi et al., Scientific Reports, doi:10.1038/s41598-022-13424-6
2 Jun 2022    Source   PDF   Share   Tweet
RCT 240 hospitalized patients with COVID-19 pneumonia, mean 9 days from the onset of symptoms, showing no significant differences with colchicine treatment. EudraCT 2020-001841-38.
risk of death, 29.4% lower, RR 0.71, p = 0.62, treatment 7 of 119 (5.9%), control 10 of 120 (8.3%), NNT 41.
risk of mechanical ventilation, 49.6% lower, RR 0.50, p = 0.29, treatment 5 of 119 (4.2%), control 10 of 120 (8.3%), NNT 24.
risk of ICU admission, 20.8% lower, RR 0.79, p = 0.67, treatment 11 of 119 (9.2%), control 14 of 120 (11.7%), NNT 41.
combined NIV/ICU/ventilation/death, 15.3% lower, RR 0.85, p = 0.62, treatment 21 of 119 (17.6%), control 25 of 120 (20.8%), NNT 31, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cecconi et al., 6/2/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, Europe, peer-reviewed, mean age 65.0, 31 authors, study period August 2020 - March 2021, average treatment delay 9.0 days.
Contact: albertocecconi@hotmail.com.
All Studies   Meta Analysis
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit